Terns Pharmaceuticals (TERN) Income towards Parent Company (2020 - 2023)
Terns Pharmaceuticals (TERN) has disclosed Income towards Parent Company for 4 consecutive years, with $69.0 million as the latest value for Q4 2023.
- For the quarter ending Q4 2023, Income towards Parent Company rose 537.89% year-over-year to $69.0 million, compared with a TTM value of -$86000.0 through Dec 2023, up 99.86%, and an annual FY2024 reading of -$88.9 million, down 45937.82% over the prior year.
- Income towards Parent Company was $69.0 million for Q4 2023 at Terns Pharmaceuticals, up from -$29.7 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $69.0 million in Q4 2023 and bottomed at -$29.7 million in Q3 2023.
- Average Income towards Parent Company over 4 years is -$9.5 million, with a median of -$13.5 million recorded in 2021.
- Peak annual rise in Income towards Parent Company hit 537.89% in 2023, while the deepest fall reached 76.63% in 2023.
- Year by year, Income towards Parent Company stood at -$11.1 million in 2020, then decreased by 29.0% to -$14.3 million in 2021, then fell by 10.03% to -$15.8 million in 2022, then skyrocketed by 537.89% to $69.0 million in 2023.
- Business Quant data shows Income towards Parent Company for TERN at $69.0 million in Q4 2023, -$29.7 million in Q3 2023, and -$17.9 million in Q2 2023.